The company, via Provectus News, circulated a white paper written by freelance medical writer Walter Alexander.
You can read the paper here, and I encourage you to do so if you already have not read it.
The paper and quotes reflect, in part, discussion about Moffitt and Provectus' work at AACR during a dinner attended by Alexander, Moffitt's Dr. Shari Pilon-Thomas, PhD, Melanoma Research Alliance's Wendy Selig, LiveSTRONG's Doug Ulman and Peter.
The white paper speaks to the overriding focus of oncology (e.g., FDA, Big Pharma, KOLs, clinicians, researchers, etc.), which is harnessing the immune system to treat and cure cancer, and the uniqueness of how PV-10 works in that regard.
I think the paper makes several tremendous points, and I will blog my thoughts in due course.
Showing posts with label Doug Ulman. Show all posts
Showing posts with label Doug Ulman. Show all posts
June 12, 2013
$PVCT White Paper: Evidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials
June 5, 2013
$PVCT Communications
The company noted, through Provectus News, that it had aired a public service announcement (of a sort) during "Melanoma Month" (May), which also included comments from corporate advisory board member and LiveSTRONG Foundation CEO Doug Ulman.
An increase in awareness of Provectus and PV-10 was reflected by a greater percentage of new visitors to the blog toward the end of the month when the announcement was first aired. % New Visits and Unique Visitors were sizably up in May.
May produced another record high for blog visitors.
An increase in awareness of Provectus and PV-10 was reflected by a greater percentage of new visitors to the blog toward the end of the month when the announcement was first aired. % New Visits and Unique Visitors were sizably up in May.
![]() |
| Click to enlarge. |
May 10, 2013
@dealbook: With Wall Street Support, @MelanomaReAlli Grows Up
A reader of the blog forwarded this article to me from Dealbook. Thank you.
"It was a “real wake-up call,” recalled the billionaire financier Leon D. Black, when his wife, Debra, received a diagnosis of melanoma in 2007. After the skin cancer was successfully treated, the experience led the Blacks to form the Melanoma Research Alliance, a group that has attracted the support of several prominent Wall Street figures. Later this month, the organization is holding its second-annual benefit geared toward the leveraged finance industry."
Read the full article here.
Individuals, like Debra Black and her husband Leon Black (and Doug Ulman), and organizations, like the Melanoma Research Alliance and its President and CEO Wendy Selig (and Livestrong), advocate for cancer patients and ultimately can play roles in the advancement of a drug candidate.
"It was a “real wake-up call,” recalled the billionaire financier Leon D. Black, when his wife, Debra, received a diagnosis of melanoma in 2007. After the skin cancer was successfully treated, the experience led the Blacks to form the Melanoma Research Alliance, a group that has attracted the support of several prominent Wall Street figures. Later this month, the organization is holding its second-annual benefit geared toward the leveraged finance industry."
Read the full article here.
Individuals, like Debra Black and her husband Leon Black (and Doug Ulman), and organizations, like the Melanoma Research Alliance and its President and CEO Wendy Selig (and Livestrong), advocate for cancer patients and ultimately can play roles in the advancement of a drug candidate.
May 2, 2013
November 16, 2012
$PVCT.OB: The First Anniversary of This Blog
I wrote my first blog post on November 16, 2011. At the time of that post: "The share price is $0.88. 14,700 shares have traded." Today, it closed at approximately $0.53, down about 40%, and traded about 54,000 shares.
![]() |
| Click on the figure to enlarge it. |
- October 29, 2012: Provectus Presents Nonclinical Data on Antitumor Immune Response to PV-10 Immuno-Chemoablation (very key),
- October 17, 2012: Provectus Pharmaceuticals Terminates Proposed Convertible Preferred Stock Offering (the failed IPO),
- October 2, 2012: Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012 (key),
- September 28, 2012: Provectus Pharmaceuticals' Patent Application Published for Combining Local and Systemic Therapies for Enhanced Treatment of Cancer (the joint Pfizer-Provectus patent app),
- September 27, 2012: Provectus Expands Protocol for Phase 1 Liver Cancer Study (important),
- June 26, 2012: Provectus Pharmaceuticals Presents Final Phase 2 on PV-10 At 2nd European Post-Chicago Melanoma Meeting 2012 on June 22, 2012 (visibility),
- May 30, 2012: Doug Ulman, National Cancer Survivorship Advocate, Joins Provectus Pharmaceuticals' Corporate Advisory Board (a great get),
- May 14, 2012: Provectus Pharmaceuticals Forms Independent Board to Meet Corporate Governance Requirements (an important corporate governance advance),
- April 10, 2012: Phase 2 Data on Provectus's PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012 (visibility),
- March 26, 2012: Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity (very key),
- March 23, 2012: Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response (very key),
- March 19, 2012: Provectus Announces Top Line Phase 2 Data For PH-10 in Its First Randomized Controlled Psoriasis Study (important), and
- January 18, 2012: Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma (important regulatory step).
![]() |
| Click on the figure to enlarge it. |
Thank you for visiting and reading!
Labels:
$PFE,
$PVCT.OB,
$PVCTP,
common stock,
Dermatology,
Doug Ulman,
Immunology,
Intellectual Property,
IPO,
Key Opinion Leaders,
Liver,
LIVESTRONG,
Management,
Melanoma,
Moffitt,
Pfizer,
PH-10,
PV-10,
Valuation
November 15, 2012
$PVCT.OB: Provectus Corporate Advisory Board Member Doug Ulman of the LIVESTRONG Foundation
Getting Doug Ulman of the LIVESTRONG Foundation (formerly The Lance Armstrong Foundation) as a corporate advisory board was a great get for Provectus.
At the time I had and, until recently, still wondered what would happen to the LIVESTRONG Foundation and brand were Lance Armstrong to fall. What happens to iconic brands when something happens to the icon: e.g., LIVESTRONG and Lance Armstrong, Apple and Steve Jobs, Berkshire Hathaway and Warren Buffett, Microsoft and Bill Gates, etc.?
The Foundation has been quick to change some name-related things.
Other things may take more time.
With Lance Armstrong stepping off the Foundation's board of directors, the brand likely will evolve as an entity unto itself, with Mr. Ulman increasing his leadership role, own brand and brand association.
He certainly appears to be paying attention to Provectus. As an aside, for now, social media, in time, should be key to spreading of awareness of PV-10 within the community of cancer patients, survivors and their family members, and far beyond.
Mr. Ulman joined Provectus' CAB nearly 6 months ago. At the time, I wrote he filled or provided the role of patient advocate on the advisory board as:
I am told activity in this regard is inbound. I, like you, will keep an eye out for all things Provectus-and-Ulman.
At the time I had and, until recently, still wondered what would happen to the LIVESTRONG Foundation and brand were Lance Armstrong to fall. What happens to iconic brands when something happens to the icon: e.g., LIVESTRONG and Lance Armstrong, Apple and Steve Jobs, Berkshire Hathaway and Warren Buffett, Microsoft and Bill Gates, etc.?
The Foundation has been quick to change some name-related things.
| Click on the figure to enlarge it. |
![]() |
| Click on the figure to enlarge it. |
![]() |
| Click on the figure to enlarge it. |
![]() |
| Click on the figure to enlarge it. |
- A three-time cancer survivor,
- Someone who already is recognized nationally and globally (growing) as a cancer advocate, and
- Chief executive of a global organization and brand.
I am told activity in this regard is inbound. I, like you, will keep an eye out for all things Provectus-and-Ulman.
July 3, 2012
It's halftime at Provectus. The company's second half is about to begin.
This ad was first shown during the televised 2012 Superbowl. I'm going to borrow from it gratuitously for this post.
It's halftime at Provectus. The company's second half is about to begin. All that matters now is looking ahead and finding a way forward. Management is in their locker room discussing what they can do to win this game in the second half. Shareholders are hurting. And they're all wondering what management is going to do to make a comeback. They're all scared, because this isn't a game.
Monthly volume grinds lower and lower.
Quarterly volume paints an even more pathetic picture.
To add insult to injury, short interest, a mostly useless statistic at this point, creeps higher.
And the stock price has been cut in half over five years.
Despite a bleak stock picture, there became something very real, very palpable, about Rose Bengal, PV-10 and Provectus in 2012's first half:
- On January 18, the FDA indicated an additional end-of-Phase 2 meeting with Provectus was not required, allowing the company to submit a design for a Special Protocol Assessment.
- On March 19, Provectus released top line Phase 2 data for PH-10's first randomized controlled psoriasis study, corroborating the drug's effectiveness in mild-to-moderate plaque psoriasis.
- On March 26, H. Lee Moffitt Cancer Center & Research Institute confirmed PV-10 chemoablation of melanoma lesions leads to a systemic response and the induction of systemic anti-tumor immunity, finding higher levels of interferon-γ, which is thought to be the quintessential cytokine mediating an immune response to melanoma.
- On April 13, MD Anderson Cancer Center's Dr. Merrick Ross updates HemOnc Today Conference attendees about intralesional ablative therapies and PV-10. What has been said in private for months and months now is said more and more in public: PV-10 should be approved as a first-line therapy now.
- On May 14, Provectus forms an independent board of directors with the addition of Jan Koe and the stepping down of the company's Dr. Eric Wachter. Earlier, in April, the NASDAQ formally lowers the requirements for stocks like PVCT to list on its exchange. In Provectus' case, a greater-than-$2-bid for 5 consecutive days only is needed.
- On May 30, the company adds Doug Ulman, national cancer survivorship advocate and president and CEO of LIVESTRONG, to its corporate advisory board.
- On June 22, Provectus releases top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma. Dr. Agarwala's presentation also reveals overall disease burden is reduced, PV-10's response is durable, and the FDA is helping to get the drug approved with an easily beatable hurdle for PV-10 in the Phase 3 trial.
- On June 26, an article in Cancer Watch highlighted Moffitt Cancer Center's studies confirming the direct effects of PV-10 chemoablation as well as its systemic response, and including powerful statements from key opinion leaders: PV-10 generates the quintessential immune response for melanoma, PV-10's induced antigen response is a surgical strike, there is no question there is a clinical need for PV-10, and the father of intralesional therapy acknowledging PV-10's promise.
- On June 29, Provectus files a mixed securities shelf of both common and preferred stock, potentially setting the stage for a strategic minority investment by a bug pharmaceutical company.
- The SPA
- A geographic-specific, indication-specific deal (or two)
- A strategic minority investment, or perhaps a larger deal of some sort including the sale of Provectus shares to a corporate
- A dermatology deal
- More Moffitt murine study results
- Moffitt human study results
- Commencement of the MM Phase 3 trial
- Progress towards accelerated approval
- More intellectual property
- A NASDAQ listing
May 30, 2012
Corporate Advisory Board Member Doug Ulman Tweets
Actually, Doug Ulman retweeted Pete's tweet about adding Doug to Provectus' corporate advisory board.
I retweeted Pete's tweet. You can follow me on Twitter here and @PVCTinvestor.
I retweeted Pete's tweet. You can follow me on Twitter here and @PVCTinvestor.
Doug Ulman, National Cancer Survivorship Advocate, Joins Provectus Pharmaceuticals’ Corporate Advisory Board
Provectus announced today that LIVESTRONG's President and CEO Doug Ulman joined its corporate advisory board. LIVESTRONG is the Lance Armstrong Foundation.
Doug Ulman is a great add for several reasons. I think is quite a coup for management. Come to think of it, "quite" is an understatement.
Mr. Ulman fills or provides the role of patient advocate on the advisory board as (i) a three-time cancer survivor, (ii) someone who already is recognized nationally as a cancer advocate, and (iii) chief executive of the global LIVESTRONG organization and brand.
You can follow Doug's tweets here. As you can see from the screenshot below, he has more than a million followers on Twitter.
His addition dramatically raises Provectus' awareness among several groups of people, including (i) cancer patients and survivors, and their families, (ii) the cancer research community (Doug served a four-year term as the Chairman of the National Cancer Institute Director's Consumer Liaison Group), (iii) the national media, and (iv) charitable and philanthropic organizations.
LIVESTRONG and Doug's use of social media and other Internet-based tools to foster communities of cancer sufferers and their families and serve as a model for other non-profit organizations is well known. See here.
Speaking of brand, Provectus now is associated with Lance Armstrong's global brand, and vice versa.
While its $50.4 million in annual revenue is less than what the 97-year-old American Cancer Society raises in a month, Livestrong has been a catalyst for better cancer care and education across the globe. "It's a force to be reckoned with," says Leslie Lenkowsky, a professor at Indiana University's Center on Philanthropy. Livestrong's help line, guidebooks, and website helped more than 400,000 people last year. Its social-media efforts reach about 3 million supporters. It has pioneered programs here and abroad for survivors; worked to unify the fractured cancer community; and instigated a worldwide crusade, which includes the United Nations and the Clinton Global Initiative, to make the world's No. 1 killer a health-care priority. "I can't think of an organization with the breadth of activity that the foundation has," says Dr. Larry Shulman, chief medical officer at the renowned Dana-Farber Cancer Institute in Boston, "and that includes the American Cancer Society." (source of October 2010 quote here).
LIVESTRONG's board members appear to be as or more prominent, influential and connected as well.
I had the good fortune many years ago to hear a keynote speech by Hamilton Jordan. It takes reminding, by oneself and others around you: There is no such thing as a bad day.
Management has been working on gaining this key opinion leader relationship for more than a year. Note Doug's tweet last April:
Let's put ourselves in Doug's shoes for a moment as he diligenced the company in order to determine whether he would or should accept Provectus' invitation to join the corporate advisory board. If you were him, what questions might you pose to management and its references? Perhaps these:
- How well does PV-10 work? How safe is it?
- What do physicians and the medical community think about PV-10?
- What does the FDA think about PV-10?
- Where is the drug in the regulatory approval process?
- How soon could PV-10 be available to patients?
- How did PV-10 come about? Is it unique? If so, why?
- How does PV-10 compare to other kinds and types of treatment?
- Who are the founders and management team? What is their background, history, and success and failures?
- Who are the members of the board of directors and advisory board?
Doug Ulman joining Provectus' advisory board speaks (shouts) volumes about PV-10, the company and management. I think it speaks to the veracity of management as well.
Subscribe to:
Posts (Atom)
























